Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 926 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Psoriatic Arthritis
Interventions: Dose A VTX958, Dose B VTX958, Placebo; Drug
Lead sponsor: Ventyx Biosciences, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 15
States / cities: Phoenix, Arizona • Newport Beach, California • Clearwater, Florida + 12 more

Conditions: Plaque Psoriasis
Interventions: DSXS topical; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Plaque Psoriasis.
Interventions: Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, Efficacy of Enbrel subcutaneously at Week 36, Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, Efficacy of Enbrel subdermally at Week 36, PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, PASI 75 n(%) subcutaneously at Week 36, PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, PASI 75 n(%) subdermally at Week 36, Adverse Reactions of Enbrel subcutaneously, Adverse Reactions of Enbrel subdermally at Week 36; Drug
Lead sponsor: ASIS Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Westminster, California

Conditions: Psoriasis
Interventions: adalimumab; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 1,469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 66
States / cities: Birmingham, Alabama • Buckner 13075 PI, Alabama • Scottsdale, Arizona + 57 more

Conditions: Psoriasis
Interventions: Dietary Counseling; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Psoriatic Arthritis
Interventions: Apremilast 30 mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Palm Desert, California • Brandon, Florida + 20 more

Conditions: Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, Psoriatic Arthritis, Proximal Humeral Fracture
Interventions: A.L.P.S. Proximal Humerus Plating System; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Psoriasis
Interventions: Drug: LYC-30937-EC, Placebo; Drug
Lead sponsor: Lycera Corp.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Carmel, Indiana • Andover, Massachusetts • Fridley, Minnesota + 4 more

Conditions: Psoriasis, Obesity
Interventions: Weight Loss; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Psoriasis
Interventions: Secukinumab Auto-Injector; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atopic Dermatitis, Psoriasis, Healthy
Interventions: AD subject visit sampling procedures, PS subject visit sampling procedures, Healthy control visit sampling procedures; Other
Lead sponsor: University of Rochester; Other
Eligibility: 13 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chronic Plaque Psoriasis
Interventions: apremilast; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Psoriasis
Interventions: Bicillin L-A; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Moderate to Severe Palmar Plantar Psoriasis
Interventions: Ustekinumab; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis
Interventions: MM-093; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Dallas, Texas • Salt Lake City, Utah

Conditions: Psoriasis
Interventions: Follow up from previous treatment with MEDI-507; Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 7
States / cities: Little Rock, Arkansas • Denver, Colorado • Alpharetta, Georgia + 4 more

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab, Adalimumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 852 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 25
States / cities: Phoenix, Arizona • San Diego, California • Tustin, California + 22 more

Conditions: Moderate to Severe Nail Psoriasis
Interventions: Secukinumab, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 9
States / cities: Birmingham, Alabama • Phoenix, Arizona • Skokie, Illinois + 6 more

Conditions: Psoriasis
Interventions: etanercept; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Psoriasis
Interventions: DFD01 Spray, Vehicle Spray; Drug
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 28
States / cities: Mobile, Alabama • Tempe, Arizona • Oceanside, California + 24 more

Conditions: Psoriasis
Interventions: Deucravacitinib, Apremilast; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Psoriasis
Interventions: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg; Drug
Lead sponsor: Centocor Research & Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more

Conditions: Psoriasis
Interventions: PH-10 (0.002% Rose Bengal), PH-10 (0.005% Rose Bengal), PH-10 (0.01% Rose Bengal), Vehicle; Drug
Lead sponsor: Provectus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Oceanside, California • Miami, Florida • New York, New York + 1 more

Conditions: Psoriasis, Immunomodulation
Interventions: tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Little Rock, Arkansas

Search by objective public record fields.

VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

ASIS for Enbrel in Plaque Psoriasis

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

Skin Microbial Ecology in Atopic Dermatitis

Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy

Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications

Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

Long-Term Follow-Up Study of Psoriasis Patients

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

The Immunological Basis for Treatment Resistance to Anti-TNF Treatments

A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Randomized Study of PH-10 for Psoriasis

Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis